Prostatype Genomics publishes Annual Report for 2025
The translated report is attached as a PDF and available on the company's webpage.
See the latest news and media coverage for Prostatype Genomics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of prognostic prostate cancer genetic test
prostatypegenomics.comLast updated
In short: Prostatype Genomics advanced its U.S. expansion by securing Medicare approval, raising capital, and publishing strong clinical validation studies.
The translated report is attached as a PDF and available on the company's webpage.
The process continues constructively but no specific date for approval is given.
The meeting will address board elections, amendment of articles, and authorization for new share issuance.
The proceeds will fund Medicare approval and commercialization in the US and Europe. The issue is covered by commitments of approximately 70 percent.
Prostatype Genomics AB today publishes its year-end report for the full year 2025, including the interim report for the second half of 2025. The full...
STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- Prostatype Genomics is currently conducting a study of 160 patients together with seven leading Spanish hospitals and the Spanish...
Prostatype Genomics AB Annual stock financials by MarketWatch. View the latest PGABF financial statements, income statements and financial ratios.
SOLNA, Sweden, May 5, 2023 /PRNewswire/ -- Prostatype Genomics AB announced today that Professor Gerald Andriole has been appointed as global Chief Medical Officer at...
Track Prostatype Genomics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Prostatype Genomics and other trending companies.